CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce ...

A new gene editing tool helps cells skip gene regions with problematic mutations. Professor Pablo Perez-Pinera, center, with ...

The critical health benefit for millions of Americans looked to be all set for a two year extension. Then Elon and Trump ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and ...

William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating on December 12.Don't Miss Our ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorization for ...

Noteworthy developments include Vertex Pharma's dominance in cystic fibrosis and Sarepta's legal victory concerning Duchenne ...

Duchenne muscular dystrophy (DMD) is one of the most common and devastating childhood genetic disorders, affecting ...

Morgan Lewis & Bockius-represented Nippon filed claims against Sarepta in the District of Delaware in July 2021, and Sarepta ...

Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.